Switching to amisulpride monotherapy for treatment-resistant schizophrenia.
The objective of this study was to assess switching to amisulpride (AMS) in treatment-resistant schizophrenia. Seven male subjects were switched to AMS and followed for 8 weeks. PANSS scores improved from 123 to 66 over this period. We conclude that AMS is of interest in the treatment of refractory schizophrenia.
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528 Athens, Greece. bkont@cc.uoa.gr
V P
VP
Kontaxakis
B J
BJ
Havaki-Kontaxaki
P P
PP
Ferentinos
K G
KG
Paplos
C R
CR
Soldatos
D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride